Drapkin et al., (2005) and Montagnana et al. (2009) observed that the levels of HE4 were significantly increased in early ovarian cancer, while the levels of CA-125 did not increase and concluded that the release of HE4 occurred earlier than CA-125 in ovarian cancer patients. This evidence concerns the gene MUC16 and ovarian cancer.